Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes.

Clin Kidney J · 2021 · PMC8894930 · PMID 35261761

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Further, these analyses showed a trend towards increased TMA recurrence in patients with complement pathogenic variants; this was particularly notable in patients with CFH and MCP variants (18.2% and 15.0% of patients with these respective variants suffered a TMA recurrence), consistent with previous reports [ 15 , 19–21 ].

also in 53,322 other papers

an increasing trendno p-value reported

The data also highlighted an increasing trend towards TMA recurrence in patients with a family history of aHUS.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.